Cibc World Markets Corp Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Cibc World Markets Corp raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 17.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 902,242 shares of the biopharmaceutical company's stock after acquiring an additional 133,084 shares during the quarter. Cibc World Markets Corp's holdings in Pfizer were worth $23,936,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after buying an additional 12,864,343 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after buying an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI increased its holdings in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after acquiring an additional 159,984 shares during the period. Parnassus Investments LLC increased its holdings in Pfizer by 3.7% during the 3rd quarter. Parnassus Investments LLC now owns 4,390,705 shares of the biopharmaceutical company's stock worth $127,067,000 after acquiring an additional 156,894 shares during the period. Finally, TrinityPoint Wealth LLC increased its holdings in Pfizer by 85.5% during the 3rd quarter. TrinityPoint Wealth LLC now owns 191,544 shares of the biopharmaceutical company's stock worth $5,543,000 after acquiring an additional 88,258 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Trading Down 0.4 %

Shares of PFE stock traded down $0.12 on Wednesday, hitting $26.19. 24,966,825 shares of the company's stock traded hands, compared to its average volume of 35,756,685. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company's fifty day simple moving average is $26.21 and its 200 day simple moving average is $27.09. The stock has a market capitalization of $148.44 billion, a price-to-earnings ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PFE. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Finally, Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.